Loading...

SER SERINA THERAPEUTICS INC US FDA Inspections 8-K Filing

SRN

SR

SERINA THERAPEUTICS INC

(SER)

2025 8-K

Regulatory Update

Financial Results Report

Annual Meeting Results

Clinical Hold Update

Funding Announcement

Convertible Note Agreement

SEC Filing Update

FDA Support Announcement

Bylaws Amendment

Market Expansion

Financial Statements

Equity Offerings

Investor Presentation

Private Placement

Conference Announcement

Financial Results

Investor Presentation

Press Release Disclosure

Financial Update

Merger and Sale

Stockholder Approvals

Clinical Trial Update

Stock Purchase Agreement

Financial Results

Investor Conference

CEO Appointment

CEO Conference Participation

Management Changes

Earnings Report

Conference Participation

Hiring of Srini Tenjarla as...

Retirement of COO

Merger and Name Change

Merger, Name Change, Earnings

Appointment of Chairman

Merger and Name Change

Financial Results Announcement

Reverse Stock Split

Credit Draw and Merger Anno...

Amendment to Promissory Note

Capital Structure Change

Credit Drawdown

Appointment of Steven Mintz...

Credit Drawdown

Indemnification Agreement

Annual Meeting of Stockholders

Credit Drawdown

Termination of Agreement

Investment and License Agre...

Credit Drawdown

Credit Drawdown

Credit Drawdown

Earnings Reports

Amendment to Convertible Pr...

Debt-Equity Swaps

Debt-Equity Swaps

Amendment to Convertible Pr...

Credit Draw and Delisting N...

Earnings Release

Credit Drawdown and Equity ...

Financial Results Announcement

Credit Drawdown

Amended Note with Juvenesce...

Borrowing and issuance of w...

External Links:

On December 10, 2025, Serina Therapeutics announced the submission of their complete response to the FDA's clinical hold letter for their SER-252 program aimed at treating advanced Parkinson's disease, addressing a regulatory concern from November 25, 2025.

AI Assistant

SERINA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.